Suppr超能文献

中国炎症性肠病患者的硫嘌呤甲基转移酶基因多态性

Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.

作者信息

Cao Qian, Zhu Qin, Shang Yan, Gao Min, Si Jianmin

机构信息

Department of Gastroenterology, Sir Run Run Shaw Institute of Clinical Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Digestion. 2009;79(1):58-63. doi: 10.1159/000205268. Epub 2009 Feb 28.

Abstract

BACKGROUND

The thiopurine drugs azathioprine and 6-mercaptopurine are well established in the treatment of inflammatory bowel disease (IBD). However, great interpatient variability exists in the efficacy and toxicity of the drugs, and this results from thiopurine methyltransferase (TPMT) gene polymorphisms. The aim of this study was to identify the TPMT gene polymorphisms in Chinese IBD patients and to study the relationship between TPMT status and thiopurine-related toxicity in these patients.

MATERIALS AND METHODS

A total of 189 IBD patients, 87 with Crohn's disease and 102 with ulcerative colitis, and 273 healthy controls were enrolled. All subjects were from the Han Chinese ethnic group. Polymorphisms in TPMT*2, *3A, *3B and *3C were analyzed using allele-specific polymerase chain reaction and polymerase chain reaction-restriction fragment length polymorphism. Direct sequencing was used to confirm the mutation results. Exons of the TPMT gene from patients who suffered from azathioprine-induced toxicity were amplified and sequenced to detect TPMT mutations.

RESULTS

No TPMT*2, 3A or 3B mutant alleles were detected. The allele frequency of TPMT3C in the IBD group was 1.59%, which was similar to that of the healthy control group (1.59 vs. 1.47%, p = 1.000). Forty-three patients were treated with azathioprine therapy, 4 experienced myelotoxicity, and 1 experienced hepatotoxicity, so the incidence of drug toxicity was 11.7% (5/43). No TPMT2, *3A, *3B or 3C polymorphisms were detected in these 5 patients. After directly sequencing the exons of the TPMT gene in these 5 patients, a synonymous single-nucleotide polymorphism (TPMT1S), which does not alter the encoded amino acid, was found in 3 patients.

CONCLUSION

TPMT*3C seemed to be a unique variant allele in this Han Chinese population. The overall frequencies of variant TPMT alleles in this population were lower than those in Caucasians, but thiopurine toxicity in Han Chinese IBD patients is not low. Factors other than TPMT polymorphisms may be responsible for the development of toxicity.

摘要

背景

硫唑嘌呤和6-巯基嘌呤等硫嘌呤类药物在炎症性肠病(IBD)的治疗中已得到广泛应用。然而,这些药物的疗效和毒性在患者之间存在很大差异,这是由硫嘌呤甲基转移酶(TPMT)基因多态性导致的。本研究的目的是确定中国IBD患者的TPMT基因多态性,并研究TPMT状态与这些患者硫嘌呤相关毒性之间的关系。

材料与方法

共纳入189例IBD患者,其中87例为克罗恩病患者,102例为溃疡性结肠炎患者,以及273例健康对照者。所有受试者均为汉族。采用等位基因特异性聚合酶链反应和聚合酶链反应-限制性片段长度多态性分析TPMT*2、*3A、3B和3C的多态性。直接测序用于确认突变结果。对硫唑嘌呤诱导毒性的患者的TPMT基因外显子进行扩增和测序,以检测TPMT突变。

结果

未检测到TPMT2、3A或3B突变等位基因。IBD组中TPMT3C的等位基因频率为1.59%,与健康对照组相似(1.59%对1.47%,p = 1.000)。43例患者接受硫唑嘌呤治疗,4例出现骨髓毒性,1例出现肝毒性,因此药物毒性发生率为11.7%(5/43)。在这5例患者中未检测到TPMT*2、3A、3B或3C多态性。对这5例患者的TPMT基因外显子进行直接测序后,在3例患者中发现了一种同义单核苷酸多态性(TPMT1S),该多态性不会改变编码的氨基酸。

结论

TPMT*3C似乎是这个汉族人群中的一个独特变异等位基因。该人群中TPMT变异等位基因的总体频率低于白种人,但中国汉族IBD患者的硫嘌呤毒性并不低。TPMT多态性以外的因素可能是毒性发生的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验